flow trial semaglutide results kidney outcomes 2024 LANDMARK ALERT 🚨 REPRIEVE Trial results: Pitavastatin provides over 35% reduction in MACE in patients with HIV! The FLOW trial for semaglutide

Mol Neurobiol (2017) 54(10):807189

Microdose Gentle, steady metabolic support on your terms

doi:10.1186/s12889-022-13944-w Grant JK, Ndumele CE, Martin SS

We conclude that semaglutide-induced reduction in obtaining rewards also affected cue and reward-related licking, but not latency, dopamine activity during reward collection and home cage chow intake

The most common side effects of GIP/GLP1 receptor agonists include nausea, vomiting, constipation, dyspepsia, and diarrhea, as shown in the SURMOUNT 3 trial

These SAEs included chest pain, infection, clotted arteriovenous fistula, catheter infection, lumbar spinal stenosis, and acute appendicitis, with most occurring in a single RCT